<DOC>
	<DOCNO>NCT02741856</DOCNO>
	<brief_summary>Research show increase dose radiotherapy improve outcomes patient lung head neck cancer . This study aim see whether also case patient tumour oesophagus . This trial compare effect standard dose radiotherapy high dose whilst closely monitoring side effect . A comparison also make regard effect standard drug use chemotherapy ( cisplatin capecitabine ) alternative combination ( carboplatin paclitaxel ) patient show response chemotherapy standard drug early treatment . All patient receive 6 week chemotherapy 5 week chemoradiotherapy . How study conduct : Prior commencement treatment patient special scan call PET scan . Patients receive second PET scan two week start standard chemotherapy . The change two scan used allocate treatment different arm study . All study subject randomise receive either standard radiotherapy dose high radiotherapy dose . The participant respond first cycle standard chemotherapy eligible take part aspect trial look alternative chemotherapy regimen . Patients randomise follow ; On basis second PET scan , patient respond standard chemotherapy allocate computer one four group detail : - Standard chemotherapy standard dose radiotherapy - Standard chemotherapy high dose radiotherapy - Alternative chemotherapy standard dose radiotherapy - Alternative chemotherapy high dose radiotherapy Patients respond standard chemotherapy ( response unknown eligible PET scan portion study ) allocate computer one two group detail : - Standard chemotherapy standard dose radiotherapy - Standard chemotherapy high dose radiotherapy The arm within group ( responder non-responders ) equal size patient allocate randomly computer . This study also compare way treatment affect two different cell type find oesophageal tumour . The effect different treatment , together cost different treatment effect quality life analyse see effective different group .</brief_summary>
	<brief_title>Study Chemoradiotherapy Oesophageal Cancer Including PET Response Dose Escalation</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Main inclusion criterion : 1 . 17 year age old . 2 . Have select receive potentially curative definitive chemoradiotherapy specialist Upper GI MDT . 3 . Histologically confirm adenocarcinoma , undifferentiated cancer squamous cell carcinoma . 4 . Tumours cervical , thoracic oesophagus , gastrooesophageal junction ( GOJ ) proximal extent disease proximal 15cm ab oral distal extent primary tumour 2 cm beyond GOJ . 5 . Tumours stag endoscopic ultrasound* , CT PETCT T14 N+/ ( provide total tumour length include node ≤10 ) . 6 . Total contiguous disease length ≤10cm define CT , EUS and/or PET . The primary tumour also ≤8cm . 7. WHO performance status 0 1 . 8 . Adequate cardiovascular function safe delivery chemoradiation opinion principal investigator . Where clinical concern patient adequate cardiac ejection fraction ≥ 40 % determine MUGA scan ECHO ( within 4 week prior enrolment ) . 9 . Adequate respiratory function safe delivery chemoradiation opinion Principal Investigator . Where clinical concern FEV1 ≥ 1 litre determine spirometry ( within 4 week prior enrolment ) . 10 . Adequate haematological , hepatic renal function 11 . Patients fit receive protocol treatment . 12 . Patients agree use effective form contraception trial ( applicable patient ) . 13 . Patients provide write informed consent prior enrolment . Additional inclusion criterion patient eligibility PET randomisation ( cisplatin/capecitabine v carboplatin/paclitaxel ) assess local centre : 14 . Baseline SUVmax ≥ 5 . 15 . PET scan 14 day start chemo ( 2/+3 day date acceptable ) 16 . Not respond early cis/cape chemotherapy ( defined patient &lt; 35 % reduction SUVmax ) 17 . For diabetic , fast Blood glucose ≤12 mmol/L . Please refer PET Imaging guidance document detail . 18 . To eligible PET randomisation , baseline PETCT must within 4 week prior start date treatment . Patients eligible trial ineligible PET randomisation randomise receive 50/60Gy radiotherapy plus cisplatin capecitabine . * Patients EUS scope unable pas eligible . Main exclusion criterion : 1 . Patients previous treatment invasive oesophageal carcinoma gastrooesophageal junction carcinoma ( include PDT laser therapy high grade dysplasia/carcinoma insitu ) . 2 . Patients metastatic disease i.e . M1a M1b accord UICC TNM version 7 . 3 . Patients active malignancy past malignancy remission le 3 year eligible trial . However , patient follow condition curatively treat NOT exclude : basal cell carcinoma , carcinomainsitu breast carcinomainsitu cervix . 4 . Patients &gt; 2cm mucosal extension tumour stomach superior extent proximal 15 cm ab oral . 5 . Patients unstable angina uncontrolled hypertension cardiac failure clinically significant cardiac disease . 6 . Patients need continue treatment contraindicate concomitant medication therapy . 7 . Patients know dihydropyrimidine dehydrogenase ( DPD ) deficiency . 8 . Patients hear impairment sensorymotor neuropathy WHO grade ≥2 . 9 . Patients serious infection ( e.g . Herpes zoster , chickenpox ) . 10 . Known hypersensitivity IMPs . 11 . Women pregnant breastfeeding . 12 . Oesophageal stent ( patient require PEG/RIG/feeding jejunostomy nutritional purpose eligible ) . 13 . Any situation , opinion local PI , make patient unsuitable candidate trial ( eg profusely bleed tumour PI concern randomisation paclitaxel/carboplatin arm risk aggravation bleed due high risk thrombocytopenia ) .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>